PURPOSE: Recently, the kinase domain mutations of epidermal growth factor receptor (EGFR) gene have been identified in non-small-cell lung cancer, and these mutations have been related to the clinical response to the tyrosine kinase inhibitor gefitinib. Gefitinib treatment has also shown clinical benefits in squamous cell carcinoma of the head and neck (SCCHN). The aim of this study was to explore the possibility that SCCHN harbored the EGFR mutations. EXPERIMENTAL DESIGN: In this study, we analyzed EGFR gene in 41 SCCHN for the detection of the somatic mutations by PCR-single-strand conformational polymorphism analysis. RESULTS: Overall, we detected three EGFR mutations (7.3%), and all of the mutations were the same in-frame deletion mutation in exon 19 (E746_A750del). CONCLUSION: These data indicated that in addition to non-small-cell lung cancer, SCCHN harbors the EGFR gene mutations, and suggested the rationale for the clinical applicability of gefinitib to SCCHN patients.
PURPOSE: Recently, the kinase domain mutations of epidermal growth factor receptor (EGFR) gene have been identified in non-small-cell lung cancer, and these mutations have been related to the clinical response to the tyrosine kinase inhibitor gefitinib. Gefitinib treatment has also shown clinical benefits in squamous cell carcinoma of the head and neck (SCCHN). The aim of this study was to explore the possibility that SCCHN harbored the EGFR mutations. EXPERIMENTAL DESIGN: In this study, we analyzed EGFR gene in 41 SCCHN for the detection of the somatic mutations by PCR-single-strand conformational polymorphism analysis. RESULTS: Overall, we detected three EGFR mutations (7.3%), and all of the mutations were the same in-frame deletion mutation in exon 19 (E746_A750del). CONCLUSION: These data indicated that in addition to non-small-cell lung cancer, SCCHN harbors the EGFR gene mutations, and suggested the rationale for the clinical applicability of gefinitib to SCCHN patients.
Authors: Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz Journal: Head Neck Date: 2012-01-27 Impact factor: 3.147
Authors: James Keller; Kenneth R Shroyer; Shishir K Batajoo; Hong-Ling Zhao; Li Ming Dong; Michael J Hayman; Edward L Chan Journal: Cancer Invest Date: 2010-09-27 Impact factor: 2.176
Authors: Carter Van Waes; Clint T Allen; Deborah Citrin; David Gius; A Dimetrios Colevas; Nancy A Harold; Susan Rudy; Liesl Nottingham; Christine Muir; Zhong Chen; Anurag K Singh; Janet Dancey; John C Morris Journal: Int J Radiat Oncol Biol Phys Date: 2009-10-30 Impact factor: 7.038
Authors: Christina I Tsien; Mukesh K Nyati; Aarif Ahsan; Susmita G Ramanand; Douglas B Chepeha; Francis P Worden; Joseph I Helman; Nisha D'Silva; Carol R Bradford; Gregory T Wolf; Theodore S Lawrence; Avraham Eisbruch Journal: Head Neck Date: 2012-08-21 Impact factor: 3.147
Authors: Nancy Van Damme; Philippe Deron; Nadine Van Roy; Pieter Demetter; Alain Bols; Jo Van Dorpe; Filip Baert; Jean-Luc Van Laethem; Franki Speleman; Patrick Pauwels; Marc Peeters Journal: BMC Cancer Date: 2010-05-11 Impact factor: 4.430